hims hers glp 1 & stock drops 30% after Novo Nordisk terminates deal Hims & Hers shares rally
Description
Diabetes 2013
Niazi explains that tirzepatide is a newer dual-agonist that targets both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor, which he says offers superior metabolic regulation and appetite suppression. Mounjaro is currently FDA-approved for type 2 diabetes, and Zepbound is also FDA-approved for weight loss
Accessed August 5, 2025.
Understanding this change could be a deciding factor in keeping coverage for Medicaid enrollees
